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a b s t r a c t
Dipyrone (metamizole) is an analgesic pro-drug used to control moderate pain. It is metabolized in two
major bioactive metabolites: 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA). The aim
of this study was to investigate the participation of peripheral CB1 and CB2 cannabinoid receptors
activation in the anti-hyperalgesic effect of dipyrone, 4-MAA or 4-AA. PGE2 (100 ng/50 mL/paw) was
locally administered in the hindpaw of male Wistar rats, and the mechanical nociceptive threshold was
quantiﬁed by electronic von Frey test, before and 3 h after its injection. Dipyrone, 4-MAA or 4-AA was
administered 30 min before the von Frey test. The selective CB1 receptor antagonist AM251, CB2 receptor
antagonist AM630, cGMP inhibitor ODQ or KATP channel blocker glibenclamide were administered
30 min before dipyrone, 4-MAA or 4-AA. The antisense-ODN against CB1 receptor expression was
intrathecally administered once a day during four consecutive days. PGE2-induced mechanical hyper-
algesia was inhibited by dipyrone, 4-MAA, and 4-AA in a dose-response manner. AM251 or ODN anti-
sense against neuronal CB1 receptor, but not AM630, reversed the anti-hyperalgesic effect mediated by
4-AA, but not by dipyrone or 4-MAA. On the other hand, the anti-hyperalgesic effect of dipyrone or
4-MAA was reversed by glibenclamide or ODQ. These results suggest that the activation of neuronal CB1,
but not CB2 receptor, in peripheral tissue is involved in the anti-hyperalgesic effect of 4-aminoantipyrine.
In addition, 4-methylaminoantipyrine mediates the anti-hyperalgesic effect by cGMP activation and KATP
opening.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Dipyrone is an analgesic pro-drug widely used in clinical practice
due to its low toxicity and efﬁcacy; however, its mechanism of action
is not fully understood (Edwards et al., 2010). It is characterized by fast
metabolism (Pierre et al., 2007) to 4-methylaminoantipyrine (4-MAA)
which is then metabolized to 4-formylaminoantipyrine (4-FAA),
4-aminoantipyrine (4-AA), and 4-acetylaminoantipyrine (4-AAA). Two
of these four metabolites, 4-AA and 4-MAA, are bioactive metabolites
and can be identiﬁed in human plasma after its oral administration.
Dipyrone is banned in some countries due to a supposed association of
4-AA with blood dyscrasias; however, the risk for blood dyscrasias
depends on factors such as dose, duration and concomitant
medication (Ibáñez et al., 2004; Maj and Centkowski, 2004; Ibrahim
et al., 2005).
Evidences demonstrated that dipyrone has analgesic action in
both peripheral tissue and the central nervous system (Beirith et
al., 1998; Abbott and Hellemans, 2000; Vazquez et al., 2007)
partially due to inhibition of cyclooxygenase-2 (COX-2), decreasing
the PGE2 synthesis (Pierre et al., 2007). In addition, other mechan-
isms underlying the analgesic effect of dipyrone have been
described. Studies have associated the dipyrone anti-hyperalgesic
effect with the activation of the L‐arginine‐NO‐cGMP pathway and
the subsequent opening of KATP channel in peripheral tissue
(Lorenzetti and Ferreira, 1996; Alves and Duarte, 2002).
In the central nervous system it has been suggested that the
activation of cannabinoid CB1 and CB2 receptors is involved in the
analgesic effect of dipyrone and its metabolites (Escobar et al., 2012;
Rogosch et al., 2012). Indeed, the anti-hyperalgesic effect of dipyrone
administered in gray periaqueductal was reversed by the admini-
stration of AM251, a CB1 receptor antagonist (Vazquez-Rodriguez
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et al., 2008). The cannabinoid receptors are located primarily in the
central nervous system, but other studies indicate that CB1 receptor is
also expressed in dorsal root ganglion (DRG) (Hohmann and
Herkenham, 1999; Ahluwalia et al., 2000) and in cutaneous terminals
of nociceptive primary afferent neurons (Ständer et al., 2005; Amaya
et al., 2006; Agarwal et al., 2007). Therefore, the aim of this study was
to verify the involvement of peripheral cannabinoid CB1 and CB2
receptors in the anti-hyperalgesic effect of dipyrone and its bioactive
metabolites, 4-MAA and 4-AA. We also veriﬁed whether the KATP
potassium channel or cGMP activation is involved in the anti-
hyperalgesic effect mediated by these molecules.
2. Materials and methods
2.1. Animals
Wistar albino rats weighing 150–200 g were used, and experi-
ments were conducted according to the guidelines of the IASP on
the use of laboratory animals (Zimmermann, 1983). All experi-
mental procedures and animal protocols were approved by the
Committee for Multidisciplinary Research in Biological Science
Area of Laboratory Animals (CEMIB), in accordance with the
guidelines of the Ethics Committee for Animal Research, State
University of Campinas. Animal suffering and the number of
animals per group were kept to a minimum.
2.2. Drugs and doses
The following drugs were used: PGE2 (100 ng/paw); AM251
a selective cannabinoid CB1 receptor antagonist (26.6, 80 and
240 mg/paw, Reis et al., 2011; Romero et al., 2013); AM630 a
selective cannabinoid CB2 receptor antagonist (16.6, 50 and
150 mg/paw, Machado et al., 2014; Romero et al., 2013); dipyrone
(8, 80, 160 and 320 mg/paw, Alves and Duarte, 2002; Parada et al.,
2003); 4-AA (4-aminoantipyrine; 8, 80, 160 and 320 mg/paw); 4-
MAA (4-methylaminoantipyrine; 8, 80, 160 and 320 mg/paw);
cGMP inhibitor ODQ (8 and 32 mg/paw, Clemente-Napimoga
et al., 2009) or KATP channel blocker glibenclamide (80 mg/paw,
Alves and Duarte, 2002). AM251, AM630, ODQ and glibenclamide
were dissolved in propylene glycol and 10% DMSO; dipyrone and
4-AA were dissolved in 0.9% NaCl. All drugs were obtained from
Sigma-Aldrich (MO, USA), except 4-MAA that was obtained from
TLC-USA.
2.3. Subcutaneous injection
Drugs or vehicle were injected subcutaneously in the rat
hindpaw (intraplantar) with a needle BD Ultra-Fines (30 gauge)
of insulin syringe (30 units). The animals were quickly contained
and the volume of 50 ml was injected.
2.4. Intrathecal injection
The method for intrathecal injection of ODN-antisense was
based on Papir-Kricheli et al. (1987). Brieﬂy, for each injection, the
rats were anesthetized with 5% halothane (Le Bars et al., 1979).
A 29 gauge needle was inserted into the subarachnoid space on
the midline between the vertebrae L4 and L5. ODN was injected at
1 μl/s. The animals recovered consciousness about 1 min after
discontinuation of anesthesia. A dose of 30 mg of antisense-ODN
against CB1 receptor was administered intrathecally in a volume of
10 ml, once daily for 4 days (Barclay et al., 2002). The behavioral
assessment was conducted on the day following the last day of
injection.
2.5. Nociceptive paw electronic pressure-meter test for rats
In a quiet room, rats were placed in acrylic cages
(122017 cm high) with a wire grid ﬂoor, 15–30 min before
testing. During this adaptation period, the paws were tested 2–3
times. The test consisted of provoking a hindpaw ﬂexion reﬂex
with a hand-held force transducer with a 0.5 mm2 polypropylene
tip (electronic von Frey hair, TC Inc. Life Science Instruments, U.S.A.).
A tilted mirror below the grid provided a clear view of the rat
hindpaw. The investigator was trained to apply the tip between
the ﬁve distal footpads with a gradual increase in pressure. The
maximal applied force was 80g. The stimulus was repeated (up to
six times, but usually, three times) until the animal presented two
similar measurements. The end point was the paw withdrawal
followed by a clear ﬂinch response. The animal was discarded if it
did not present a consistent response. The measurement of the
pressure (calibrated in grams) was automatically recorded when
the paw was withdrawn. The results, intensity of hyperalgesia,
were presented as Δ withdraw threshold. The intensity of hyper-
algesia was obtained by subtracting values measured at the
deﬁned time interval from those obtained in the control period,
that is, before the injections.
2.6. Antisense oligodeoxynucleotides (ODNs)
The functional blockade of the CB1 receptor expression in
peripheral sensory neurons was carried out by intrathecal injec-
tion of antisense-ODN (Oliveira et al., 2009; Yu et al., 2009; Prado
et al., 2013). The following antisense-ODN sequence was used: 50–
GAGACAACAGAGTTCTAAG–30, the mismatch-ODN sequence, 50–
GAGACATCAGAGAGATCTAAT–30, corresponded to the antisense
sequence except that six bases were changed. A search of the
NCBI database to Rattus norvegicus did not identify other homo-
logous sequences. The lyophilized ODN was purchased from Alere
(SP, Brazil) and reconstituted in 0.9% NaCl. The ODN was aliquoted
and stored at 20 1C.
2.7. Western blotting analysis of CB1 receptor expression
For analysis of the expression of cannabinoid CB1 receptor, after
intrathecal administration of antisense-ODN we collected L4–L5
DGR. The ganglia were frozen in liquid nitrogen and stored at
80 1C until use for analysis of the expression of CB1 receptor.
Previously stored samples L4–L5 DRG were homogenized with an
ultrasonic homogenizer (Sonic Corporation, USA) in a buffer
containing 1% Triton X-100, 50 mM phosphate buffer pH 7.4, 8 M
urea, 2 M thiourea, 1 mM EDTA, 1% protease inhibitor mix com-
plete (P8340, Sigma, USA) at 4 1C. After 20 min incubation at 4 1C,
samples were centrifuged at 12000g for 15 min at 4 1C and the
resulting supernatant was transferred to a new tube. Protein
concentration was determined by the Bradford method and
70 mg of total proteins for each sample were separated by SDS-
PAGE and transferred to nitrocellulose membrane according to
standard techniques. The membranes were stained with Ponceau S
USB™ and photodocumented to quantify the total protein content
as a control of protein loading (Romero-Calvo et al., 2010; Ignarro
et al., 2013).
Membranes were blocked with 5% non-fat dry milk solution in
PBS containing 0.1% tween-20, and incubated overnight with goat
polyclonal CB1 receptor antibody (1:1000; SAB2500190; Sigma-
Aldrich, MO, USA), followed by rabbit anti-goat HRP conjugated
secondary antibody (1:10000; 81620; Zymed – Life Technologies;
CA, USA). Immunoreactive bands were detected by using chemi-
luminescence kit SuperSignal West Pico (Pierce), photodocumen-
ted and quantiﬁed (GeneTools Software, Syngene). Thus, for each
sample, it was calculated the ratio between the optical density
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(OD) of CB1 band and the OD corresponding to all protein bands
stained with Ponceau S. This procedure allowed the use of OD
value of all protein bands as an internal control.
2.8. Statistical analysis
To determine if there were signiﬁcant differences (Po0.05)
between groups, one-way ANOVA or unpaired t-test was per-
formed. The statistical analysis of the results obtained was
performed in the GraphPad Prism v4.00 for Windows (GraphPad
Software). The results were presented as the mean7S.E.M of six
rats per group. The differences between the groups were com-
pared using one-way ANOVA to obtain the degree of signiﬁcance,
followed by the Tukey's multiple comparison test to compare the
groups and doses (behavioral experiments). The data from Wes-
tern blot were expressed in arbitrary units.
3. Results
3.1. Local administration of dipyrone, 4-methylaminoantipyrine
(4-MAA) or 4-aminoantipyrine (4-AA) in peripheral tissue reduces
the PGE2-induced hyperalgesia
Local administration of PGE2 (100 ng/paw) in subcutaneous
tissue of rat hindpaw induced mechanical hyperalgesia measured
3 h after its injection. Dipyrone or its metabolites, 4-MAA or 4-AA
(all 8; 80; 160 or 320 mg/paw), were administered at the same site
2.5 h after PGE2. As shown in Fig. 1, dipyrone (Fig. 1A), 4-MAA
(Fig. 1B) or 4-AA (Fig. 1C) decrease the mechanical hyperalgesia in
a dose-related manner (one-way ANOVA, Tukey's test, Po0.05).
The administration of 160 μg/paw of dipyrone, 4-MAA or 4-AA in
the contralateral hindpaw did not change the mechanical with-
drawal threshold, ruling out their systemic effect. This dose was
used in the following experiments.
3.2. The anti-hyperalgesic effect of dipyrone is mediated by cGMP
activation and KATP potassium channel opening, but not by
cannabinoid CB1 or CB2 receptor activation
The local administration of dipyrone (160 μg/paw) in the sub-
cutaneous tissue reduced the PGE2-induced mechanical hyperalgesia.
As shown in Fig. 2A, this reduction is reversed by local administration
of ODQ (8 or 32 μg/paw) or glibenclamide (80 μg/paw), 30 min
before dipyrone injection (one-way ANOVA, Tukey's test, Po0.05).
The pretreatment with AM251 (Fig. 2B; 26.6, 80 and 240 mg/paw) or
AM630 (Fig. 2C; 16.6, 50 and 150 mg/paw) 30 min before dipyrone
injection did not reverse its anti-hyperalgesic effect (one-way
ANOVA, Tukey's test, P40.05). The local administration of AM251
(80 mg/paw) or AM630 (50 mg/paw) by itself has no effect on PGE2-
induced mechanical hyperalgesia (Fig. 2B and 2C, respectively).
3.3. The anti-hyperalgesic effect of 4-methylaminoantipyrine is
mediated by cGMP activation and KATP potassium channel opening,
but not by cannabinoid CB1 or CB2 receptor activation
The local administration of 4-MAA (160 μg/paw) in the subcuta-
neous tissue reduced the PGE2-induced mechanical hyperalgesia.
Fig. 1. Local administration of dipyrone, 4-methylaminoantipyrine (4-MAA) or 4-aminoantipyrine (4-AA) in peripheral tissue reduces the PGE2-induced hyperalgesia.
Dipyrone (Dipy), 4-AA or 4-MAA administered in the hindpaw 2.5 h after PGE2 inhibited in a dose-dependent manner the mechanical hyperalgesia evaluated 30 min later
(A, B, C, respectively ). Dipyrone, 4-MAA and 4-AA 160 μg/paw, but not 320 μg/paw, administered in contra-lateral paw (Ct) do not change the mechanical withdrawal
threshold, ruling out its systemic effect. The symbol n means different from control group (0.9% NaCl administration; 50 μL), # and 1 mean different from PGE2 group
(one-way ANOVA, Tukey's test, Po0.05).
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As shown in Fig. 3A, this reduction is reversed by local administration
of ODQ (8 or 32 μg/paw) or glibenclamide (80 μg/paw), 30 min before
4-MAA injection (one-way ANOVA, Tukey's test, Po0.05). The pre-
treatment with AM251 (Fig. 3B; 26.6, 80 and 240 mg/paw) or AM630
(Fig. 3C; 16.6, 50 and 150 mg/paw) 30min before 4-MAA injection did
not reverse its anti-hyperalgesic effect (one-way ANOVA, Tukey's test,
P40.05).
3.4. The anti-hyperalgesic effect of 4-aminoantipyrine is mediated by
cannabinoid CB1 receptor activation, but not CB2 or cGMP activation
and KATP potassium channel opening
The local administration of 4-AA (160 μg/paw) in the subcuta-
neous tissue reduced the PGE2-induced mechanical hyperalgesia.
As shown in Fig. 4A, this reduction is reversed by local adminis-
tration of selective antagonist of cannabinoid CB1 receptors AM251
(80 and 240 mg/paw). The pretreatment with antagonist of canna-
binoid CB2 receptors AM630 (Fig. 4B; 16.6, 50 and 150 mg/paw),
ODQ or glibenclamide (8 and 32 μg/paw or 80 μg/paw, respec-
tively; Fig. 4C) 30 min before 4-MAA injection did not reverse its
anti-hyperalgesic effect (One-way ANOVA, Tukey's test, P40.05).
3.5. The intrathecal treatment with antisense-ODN against
cannabinoid CB1 receptor in peripheral tissue reduce
anti-hyperalgesic effect of 4-AA
The local administration of 4-AA (160 μg/paw) in the subcuta-
neous tissue reduced the PGE2-induced mechanical hyperalgesia.
As shown in Fig. 5A, this reduction is reversed by intrathecal
administration of antisense ODN against CB1 receptor (30 mg/10 ml
once daily for 4 days), but not its mismatch (One-way ANOVA,
Tukey's test, P40.05). The administration of antisense-ODN
reduced CB1 receptor expression on DRG as shown by Western
blotting (Fig. 5B; Po0.05, unpaired t-test).
4. Discussion and conclusions
Dipyrone is a pro-drug, widely marketed since 1922, due to its
potent analgesic and antipyretic effects (Ferreira, 2002; Parada
et al., 2003;). Dipyrone is rapidly hydrolyzed (Pierre et al., 2007;
Rogosch et al., 2012) in 4-methylaminoantipyrine (4-MAA) which
is then metabolized to 4-formylaminoantipyrine (4-FAA),
4-aminoantipyrine (4-AA), and 4-acetylaminoantipyrine (4-AAA).
4-MAA and 4-AA are the bioactive metabolites mostly detected in
Fig. 2. Anti-hyperalgesic effect of dipyrone mediated by cGMP and KATP, but not CB1 or CB2 receptor activation. Local administration of PGE2 in rat's hindpaw induced
mechanical hyperalgesia 3 h after, which is decreased with dipyrone administered 2.5 h after PGE2. This anti-hyperalgesic effect is reversed by glibenclamide or ODQ (A), but
not by AM251 (B) or AM630 (C). AM251 or AM630 has no effect on PGE2-induced mechanical hyperalgesia (B, C). The symbol n means different from control group (0.9%
NaCl; 50 μL), # means different from others groups (one-way ANOVA, Tukey's test, Po0.05). The administration of vehicle does not change the mechanical withdraw
threshold by itself.
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human plasma after oral administration, presenting analgesic
effect (Volz and Kellner, 1980; Zylber-Katz et al., 1992).
Our results conﬁrm literature data showing that dipyrone,
4-MAA and 4-AA locally administered in peripheral tissue inhibit
the hyperalgesia induced by PGE2 (Ferreira, 2002; Assis et al., 2013 ).
The proﬁle of the anti-hyperalgesic effect mediated by dipyrone and
4-MAA is quite similar; however it is important to note that the
hydrolysis of dipyrone to 4-MAA is a non-enzymatic reaction and
depends on concentration, pH and temperature (Pierre et al., 2007).
Therefore, it is plausible that the anti-hyperalgesic effect of dipyr-
one, at least in part, is mediated by 4-MAA resulting of local
dipyrone hydrolysis.
It has been proposed that cyclooxygenase-2 (COX-2) inhibition
plays an important role in the pharmacological effects of dipyrone
in the CNS (Hinz et al., 2007). In fact, all metabolites of dipyrone
show a low binding to plasma proteins and are distributed
homogeneously and quickly throughout the body due to their
ability to easily cross the blood–brain barrier. Furthermore dipyr-
one preferentially decreases COX-2 activity but not COX-1 in the
peripheral tissue (Hinz et al., 2007; Pierre et al., 2007). However, in
spite of its COX-2 inhibitory effect, this study conﬁrms that
dipyrone reverses the hyperalgesia induced by PGE2 (Ferreira,
2002) demonstrating that its analgesic effect does not depend on
its anti-inﬂammatory effect. In addition, the analgesic doses of
dipyrone are signiﬁcantly lower than their anti-inﬂammatory
doses (Coersmeier et al., 1986). The anti-hyperalgesic effect of
dipyrone has been associated to the L‐arginine‐NO‐cGMP pathway
activation and the subsequent opening of KATP channel in periph-
eral afferent nociceptor (Lorenzetti and Ferreira, 1996; Alves and
Duarte, 2002).
The ﬁndings of this study showed that, similarly to dipyrone,
the anti-hyperalgesic effect of 4-MAA metabolite is mediated by
cGMP activation and KATP channel opening, demonstrating that
the L‐arginine‐NO‐cGMP‐KATP pathway activation underlies its
effect. This fact reinforces the hypothesis that the effect of
dipyrone may be mediated by its hydrolyzed metabolite 4-MAA.
In contrast, the anti-hyperalgesic effect of 4-AA does not depend
on cGMP activation neither KATP channel opening, suggesting that
L‐arginine‐NO‐cGMP‐KATP pathway is not involved in its mechan-
ism of action.
Data of this study demonstrated that the anti-hyperalgesic
effect of 4-AA, but not dipyrone or 4-MAA, is associated with
cannabinoid CB1 receptor activation. In fact, it has been shown that
the endogenous cannabinoid system may play a role in the
dipyrone effects (Escobar et al., 2012; Rogosch et al., 2012). In
addition, this study showed that cannabinoid CB2 receptor did not
mediate the anti-hyperalgesic effect of dipyrone, 4-MAA or 4-AA
on PGE2-induced hyperalgesia. However, these ﬁndings do not
exclude the possible involvement of cannabinoid CB2 receptor in
the dipyrone-induced analgesia; once previous studies using
formalin (Hanus et al., 1999) and carrageenan (Clayton et al.,
2002) demonstrated that the activation of cannabinoid CB2
Fig. 3. Anti-hyperalgesic effect of 4-methylaminoantipyrine mediated by cGMP and KATP, but not CB1 or CB2 receptor activation. Local administration of PGE2 in rat's
hindpaw induces mechanical hyperalgesia 3 h after, which is decreased with 4-MAA administered 2.5 h after PGE2. This anti-hyperalgesic effect is reversed by glibenclamide
or ODQ (A), but not by AM251 (B) or AM630 (C). The symbol n means different from control group (0,9% NaCl; 50 μL), # means different from others groups (one-way
ANOVA, Tukey's test, Po0.05). The administration of vehicle does not change the mechanical withdraw threshold by itself.
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receptor contributes to analgesia. It is important to emphasize that
PGE2 directly acts on EP receptors of primary afferent nociceptors
by sensitizing them. Since cannabinoid CB2 receptor is not
expressed in neurons, the present study is not able to reveal the
effect of cannabinoid CB2 receptor activation. Thus, these data
suggest that, in spite of the indirect action of dipyrone and its
metabolites activating cannabinoid CB2 receptor, the activation of
cannabinoid CB1 receptor or the activation of L‐arginine‐NO‐
cGMP‐KATP pathway is enough to induce anti-hyperalgesic effect.
The activation of cannabinoid CB1 receptors by dipyrone was
previously demonstrated (Escobar et al., 2012; Rogosch et al.,
2012), however agreeing with the ﬁndings of this study, only 4-
AA activated cannabinoid CB1 receptors. To conﬁrm the involve-
ment of neuronal cannabinoid CB1 receptor in primary afferent
nociceptor, rats were treated with anti-sense ODN to knock down
this protein only in neurons of peripheral tissue. As demonstrated
in this study, rats with low levels of CB1 expression in DRG were
less responsive to local administration of 4-AA in the peripheral
tissue.
It has been demonstrated that CB1 receptor activation nega-
tively modulates transient receptors potential vanniloid TRPV1
channels (Yang et al., 2013; Gábor and László, 2009). Indeed, PGE2
acting on neuronal EP receptor positively modulates adenylyl
cyclase activity and subsequently cyclic AMP-dependent protein
kinase (PKA) (Ferreira and Nakamura, 1979; Villarreal et al., 2009).
In contrast, CB1 receptor activation reduces adenylyl cyclase
activity and subsequently PKA. Once PGE2-induced PKA phosphor-
ylates TRPV1, contributing to neuronal sensitization (Schnizler et
al., 2008), it is plausible to hypothesize that CB1 receptor activation
by 4-AA reduces inﬂammatory hyperalgesia by the reduction of
PKA activity and the subsequently TRPV1 phosphorylation. Our
results, however, have shown that local administration of dipyr-
one, but not 4-AA, reduces the capsaicin-induced nociception in
rats hindpaw (unpublished data). This ﬁnding suggests that CB1
receptor activation by 4-AA negatively modulates (Yang et al.,
2013), but does not prevent the TRPV1 receptor activation in
primary afferent nociceptor. In addition CB1 receptor activation on
immune cells of peripheral tissue can also negatively modulate the
inﬂammatory hyperalgesia (Gaffal et al., 2013).
5. Conclusion
The present ﬁndings show that dipyrone induces analgesia by
two different mechanisms of action in the peripheral tissue:
Fig. 4. Anti-hyperalgesic effect of 4-aminoantipyrine mediated by CB1 receptor activation but not CB2 or cGMP and KATP. Local administration of PGE2 in rat's hindpaw
induces mechanical hyperalgesia 3 h after, which is decreased with 4-AA administered 2.5 h after PGE2. This anti-hyperalgesic effect is reversed by AM251 (A) but not by
AM630 (B); glibenclamide or ODQ (C). The symbol n means different from control group (0.9% NaCl; 50 μL), # means different from PGE2 group (one-way ANOVA, Tukey's
test, Po0.05). The administration of vehicle does not change the mechanical withdraw threshold by itself.
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activation of L‐arginine‐NO‐cGMP‐KATP pathway by 4-MAA and
neuronal cannabinoid CB1 receptor activation by 4-AA.
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